Please use this identifier to cite or link to this item:
Título : Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
Autor : Cardinali, Daniel Pedro 
Cano Barquilla, Pilar 
Jiménez Ortega, Vanesa 
Esquifino, Ana I. 
Fecha de publicación : 2011
Editorial : Karger Publishers
Cita : Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en:
Resumen : Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.
ISSN : 0028-3835 (Print)
1423-0194 (Online)
Disciplina: MEDICINA
DOI: 10.1159/000324699
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
melatonin-metabolic-syndrome-physiopathologic.pdf580,07 kBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Aug 11, 2022


checked on Aug 11, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons